Nu Skin Enterprises (NUS) Receives “Buy” Rating from Pivotal Research

Pivotal Research reiterated their buy rating on shares of Nu Skin Enterprises (NYSE:NUS) in a research report report published on Friday morning. They currently have a $90.00 target price on the stock.

“We think 2018 might be bigger than usual – for Repo which again, is not in guidance.”,” Pivotal Research’s analyst wrote.

A number of other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Nu Skin Enterprises from a hold rating to a sell rating in a research note on Wednesday, December 20th. ValuEngine upgraded shares of Nu Skin Enterprises from a hold rating to a buy rating in a research note on Sunday, December 31st. Finally, Citigroup reiterated a buy rating and issued a $81.00 target price (up from $70.00) on shares of Nu Skin Enterprises in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $68.88.

Nu Skin Enterprises (NYSE NUS) traded down $3.70 on Friday, reaching $69.07. 1,010,942 shares of the company’s stock were exchanged, compared to its average volume of 348,543. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $3,831.34, a PE ratio of 29.14, a price-to-earnings-growth ratio of 2.26 and a beta of 1.46. Nu Skin Enterprises has a 52-week low of $47.10 and a 52-week high of $74.45.

Nu Skin Enterprises (NYSE:NUS) last released its earnings results on Thursday, February 15th. The company reported $1.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.19 by $0.01. The firm had revenue of $666.20 million for the quarter, compared to analysts’ expectations of $667.39 million. Nu Skin Enterprises had a net margin of 5.68% and a return on equity of 25.25%. The company’s quarterly revenue was up 25.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.79 earnings per share. sell-side analysts expect that Nu Skin Enterprises will post 3.65 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 14th. Investors of record on Monday, February 26th will be paid a dividend of $0.365 per share. This is a boost from Nu Skin Enterprises’s previous quarterly dividend of $0.36. This represents a $1.46 dividend on an annualized basis and a dividend yield of 2.11%. The ex-dividend date is Friday, February 23rd. Nu Skin Enterprises’s dividend payout ratio is presently 60.76%.

In related news, Chairman Steven Lund sold 42,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $68.11, for a total transaction of $2,860,620.00. Following the sale, the chairman now directly owns 4,769 shares in the company, valued at approximately $324,816.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 195,978 shares of company stock worth $13,512,733 over the last 90 days. 5.20% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in NUS. Wolverine Asset Management LLC lifted its stake in shares of Nu Skin Enterprises by 106.9% during the 4th quarter. Wolverine Asset Management LLC now owns 1,514 shares of the company’s stock valued at $103,000 after buying an additional 23,378 shares in the last quarter. Cerebellum GP LLC bought a new stake in Nu Skin Enterprises during the 4th quarter worth approximately $124,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Nu Skin Enterprises during the 3rd quarter worth approximately $148,000. Amundi Pioneer Asset Management Inc. bought a new stake in Nu Skin Enterprises during the 4th quarter worth approximately $192,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Nu Skin Enterprises by 38.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock worth $210,000 after acquiring an additional 858 shares during the period. Institutional investors own 77.00% of the company’s stock.

WARNING: This piece of content was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/17/nu-skin-enterprises-nus-receives-buy-rating-from-pivotal-research.html.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply